Article
Gastroenterology & Hepatology
Helene Hermand, Jeremie H. Lefevre, Conor Shields, Najim Chafai, Clotilde Debove, Laurent Beaugerie, Magali Svrcek, Yann Parc
Summary: The study found that a small proportion of patients undergoing subtotal colectomy may have their diagnosis changed from ulcerative colitis to Crohn's disease postoperatively, with patients with a disease duration of less than 10 years and an initial diagnosis of IBDU being at higher risk for this diagnostic change.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
(2021)
Review
Biochemistry & Molecular Biology
Vishal Khatri, Ramaswamy Kalyanasundaram
Summary: This review focuses on the association between IBD and gut inflammasome, as well as recent advances in research and therapeutic strategies for IBD, discussing inflammasomes and their components, outcomes from experimental animals and human studies, inflammasome inhibitors, and developments in inflammasome-targeted therapies for IBD.
Review
Biochemistry & Molecular Biology
HyunTaek Jung, Jae Seok Kim, Keum Hwa Lee, Kalthoum Tizaoui, Salvatore Terrazzino, Sarah Cargnin, Lee Smith, Ai Koyanagi, Louis Jacob, Han Li, Sung Hwi Hong, Dong Keon Yon, Seung Won Lee, Min Seo Kim, Paul Wasuwanich, Wikrom Karnsakul, Jae Il Shin, Andreas Kronbichler
Summary: Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract that mainly affects young people. Recent studies have shown that microRNAs (miRNAs) play an important role in the pathogenesis, diagnosis, and treatment of IBD.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
(2021)
Review
Gastroenterology & Hepatology
Esther Orlanski-Meyer, Martine Aardoom, Amanda Ricciuto, Dan Navon, Nicholas Carman, Marina Aloi, Jiri Bronsky, Jan Daebritz, Marla Dubinsky, Seamus Hussey, Peter Lewindon, Javier Martin De Carpi, Victor Manuel Navas-Lopez, Marina Orsi, Frank M. Ruemmele, Richard K. Russell, Gabor Veres, Thomas D. Walters, David C. Wilson, Thomas Kaiser, Lissy de Ridder, Anne Griffiths, Dan Turner
Summary: By surveying experts and conducting systematic reviews, key predictors for pediatric UC outcomes, including colectomy, acute severe colitis, and cancer, were identified. These predictions can be used for personalized treatment approaches, improving outcomes for pediatric UC patients.
Article
Gastroenterology & Hepatology
Uma Mahadevan, Millie D. Long, Sunanda Kane, Abhik Roy, Marla C. Dubinsky, Bruce E. Sands, Russell D. Cohen, Christina D. Chambers, William J. Sandborn
Summary: The study found that exposure to biologic, thiopurine, or combination therapy during pregnancy did not increase adverse maternal or fetal outcomes, and these treatments can be continued throughout pregnancy for women with IBD to maintain disease control.
Article
Medicine, General & Internal
Silvia Salvatori, Francesco Baldassarre, Michelangela Mossa, Giovanni Monteleone
Summary: Long COVID is common in patients with inflammatory bowel diseases (IBD), with fatigue being the most frequent symptom. It does not influence the frequency of IBD relapses, but is more prevalent in female patients.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Gastroenterology & Hepatology
Thomas M. Goodsall, Tran M. Nguyen, Claire E. Parker, Christopher Ma, Jane M. Andrews, Vipul Jairath, Robert Bryant
Summary: The study systematically identified ultrasound scoring indices for assessing inflammatory bowel disease activity, with common components including bowel wall thickness, colour Doppler imaging, and bowel wall stratification. The correlation between ultrasound indices and reference standards, as well as sensitivity, specificity, accuracy, and other properties, varied within certain ranges. However, reliability and responsiveness data were limited, and most studies were rated with unclear or high risk of bias.
JOURNAL OF CROHNS & COLITIS
(2021)
Review
Medicine, General & Internal
Katarzyna Akutko, Andrzej Stawarski
Summary: Inflammatory bowel diseases (IBD) are chronic inflammatory diseases of the digestive tract with periods of remission and relapses. The etiopathogenesis is not fully understood, leading to only symptomatic treatment. There is a constant need to search for new high safety profile therapies for IBD.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Biotechnology & Applied Microbiology
Guihua Chen, Jun Shen
Summary: Inflammatory bowel disease (IBD) is a global disease with high morbidity and medical costs. Early diagnosis and intervention are crucial for controlling its progression.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
(2021)
Editorial Material
Gastroenterology & Hepatology
Catherine Le Berre, Laurent Peyrin-Biroulet
Summary: The SPIRIT consensus group has agreed that the ultimate therapeutic goal in both CD and UC is to prevent disease impact on patients' lives, including health-related quality of life, disability, and fecal incontinence, as well as prevent complications in the short and long term, such as bowel damage, surgeries, disease extension, extraintestinal manifestations, and dysplasia or cancer. These recommendations will need to be validated in clinical studies before being implemented in disease-modification trials.
Article
Multidisciplinary Sciences
Ryan W. Gan, Diana Sun, Amanda R. Tatro, Shirley Cohen-Mekelburg, Wyndy L. Wiitala, Ji Zhu, Akbar K. Waljee
Summary: This study replicated a machine-learning model's ability to predict acute exacerbations of inflammatory bowel disease (IBD) in a nationally representative cohort, with the random forest model outperforming the logistic regression model.
Review
Medicine, General & Internal
Elisabetta Antonelli, Gabrio Bassotti, Marta Tramontana, Katharina Hansel, Luca Stingeni, Sandro Ardizzone, Giovanni Genovese, Angelo Valerio Marzano, Giovanni Maconi
Summary: This review summarizes the dermatologic manifestations occurring in patients with inflammatory bowel diseases, including specific manifestations, cutaneous disorders associated with IBDs, reactive mucocutaneous manifestations of IBDs, mucocutaneous conditions secondary to treatment, and manifestations due to nutritional malabsorption. An accurate dermatological examination is crucial in all IBD patients, especially in candidates to biologic therapies where drug-induced cutaneous reactions may be clinically relevant.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Medicine, General & Internal
Anastasia Katsoula, Georgios Axiaris, Afroditi Mpitouli, Maria Palatianou, Angeliki Christidou, Nikolaos Dimitriadis, Andreas Nakos, Ploutarchos Pastras, Panagiotis Kourkoulis, Pantelis Karatzas, Miltiadis Moutzoukis, Charalampos Zlatinoudis, Athanasios Philippidis, Anastasia Kourikou, Georgios Kokkotis, Antonios Gklavas, Angeliki Machaira, Aikaterini Mantaka, Persefoni Talimtzi, Evaggelia Anagnostopoulou, Ioannis E. Koutroubakis, Ioannis Papaconstantinou, Georgios Bamias, Spilios Manolakopoulos, Nicoletta Mathou, Konstantina Paraskeva, Andreas Protopappas, Eftychia Tsironi, Konstantinos H. H. Katsanos, Dimitrios K. K. Christodoulou, Georgios Papatheodoridis, Georgios Michalopoulos, Georgios Theocharis, Christos Triantos, Ioannis Pachiadakis, Konstantinos Soufleris, Nikolaos Viazis, Gerassimos J. Mantzaris, Georgios Tribonias, Maria Tzouvala, Angeliki Theodoropoulou, Konstantinos Karmiris, Evanthia Zampeli, Spyridon Michopoulos, Anna-Bettina Haidich, Olga Giouleme
Summary: The aim of this study was to validate the content of IBD-Disk in a Greek cohort of IBD patients. The results showed good correlation and consistency between the scores of IBD-Disk and IBD-DI at baseline and follow-up. Female gender and extraintestinal manifestations were significantly associated with a higher IBD-Disk total score. Therefore, the Greek version of IBD-Disk was proven to be a reliable and valid tool for assessing IBD-related disability.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Gastroenterology & Hepatology
Jee Hyun Kim, Chang-Myung Oh, Jun Hwan Yoo
Summary: Obesity is common in patients with inflammatory bowel disease (IBD), especially in newly developed countries. It has been suggested that 15%-40% of IBD patients are obese, and obesity may play a role in the development of IBD. Dysfunction of mesenteric fat can worsen the inflammation in Crohn's disease and lead to the formation of strictures or fistulas. Additionally, obesity can affect the course of the disease and the response to treatment in IBD. As a result, obesity control is being proposed as a novel management approach for IBD, and this review aims to discuss the impact of obesity on IBD treatment outcomes and the current status of pharmacologic or surgical anti-obesity treatments in IBD patients.
WORLD JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Vu Q. Nguyen, Fabiano Celio, Maithili Chitnavis, Mohammad Shakhatreh, Jeffry Katz, Fabio Cominelli, Amitabh Chak, Paul Yeaton
Summary: This study examined the role of EUS in distinguishing between Crohn's disease and ulcerative colitis, finding that it can be used to diagnose active and inactive disease by measuring colon wall layer thickness and assessing transmural disease activity.
GASTROINTESTINAL ENDOSCOPY
(2023)
Article
Gastroenterology & Hepatology
William J. Sandborn, Julian Panes, Silvio Danese, Zaineb Sharafali, Azra Hassanali, Rhian Jacob-Moffatt, Christopher Eden, Marco Daperno, John F. Valentine, David Laharie, Carolina Baia, Raja Atreya, Remo Panaccione, Grazyna Rydzewska, Humberto Aguilar, Severine Vermeire
Summary: This study compared the safety and efficacy of two doses of Etrolizumab with placebo in patients with Crohn's disease. The results showed that during the maintenance phase, Etrolizumab significantly improved clinical remission and endoscopic improvement in patients with moderately to severely active Crohn's disease compared to placebo. However, there was no significant difference in the effects of Etrolizumab and placebo on clinical remission and endoscopic improvement during the induction phase.
LANCET GASTROENTEROLOGY & HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Marietta Iacucci, Tommaso Lorenzo Parigi, Rocio Del Amor, Pablo Meseguer, Giulio Mandelli, Anna Bozzola, Alina Bazarova, Pradeep Bhandari, Raf Bisschops, Silvio Danese, Gert De Hertogh, Jose G. Ferraz, Martin Goetz, Enrico Grisan, Xianyong Gui, Bu Hayee, Ralf Kiesslich, Mark Lazarey, Remo Panaccione, Adolfo Parra-Blanco, Luca Pastorelli, Timo Rath, Elin S. Royset, Gian Eugenio Tontini, Michael Vieth, Davide Zardo, Subrata Ghosh, Valery Naranjo, Vincenzo Villanacci
Summary: An artificial intelligence computer-aided diagnosis system was developed and validated to evaluate UC biopsies and predict prognosis. The system showed high accuracy and sensitivity in assessing biopsy results and predicting outcomes.
Article
Gastroenterology & Hepatology
Haim Leibovitzh, Sun-Ho Lee, Juan Antonio Raygoza Garay, Osvaldo Espin-Garcia, Mingyue Xue, Anna Neustaeter, Ashleigh Goethel, Hien Q. Huynh, Anne M. Griffiths, Dan Turner, Karen L. Madsen, Paul Moayyedi, A. Hillary Steinhart, Mark S. Silverberg, Colette Deslandres, Alain Bitton, David R. Mack, Kevan Jacobson, Maria Cino, Guy Aumais, Charles N. Bernstein, Remo Panaccione, Batia Weiss, Jonas Halfvarson, Wei Xu, Williams Turpin, Kenneth Croitoru
Summary: This study identified serum proteomic signatures associated with future development of Crohn's disease (CD), reflecting potential early biological processes of immune and barrier dysfunction.
Article
Gastroenterology & Hepatology
Michael J. Buie, Stephanie Coward, Abdel-Aziz Shaheen, Jayna Holroyd-Leduc, Lindsay Hracs, Christopher Ma, Remo Panaccione, Eric Benchimol, Charles N. Bernstein, Alain Bitton, Anthony R. Otley, Jennifer L. Jones, Sanjay K. Murthy, M. Ellen Kuenzig, Juan-Nicolas Pena-Sanchez, Laura E. Targownik, Harminder Singh, Antonio Avina-Zubieta, Gilaad G. Kaplan
Summary: Recent advances in IBD management have led to a decrease in hospitalization rates for IBD-related and non-IBD-related causes. The study observed a decline in all-cause hospitalization rates as well.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Gastroenterology & Hepatology
Florence-Damilola Odufalu, Marla C. Dubinsky, Laurent Peyrin-Biroulet, Karoliina Ylanne, Allyson Sipes, Joseph C. Cappelleri, Leo J. Russo, Michelle Segovia, Sean Gardiner, Edward P. Johnson, Amy Mulvey, Remo Panaccione
Summary: This study investigated the impact of patient demographics and psychological comorbidities on disease management and health care experience in patients with ulcerative colitis, highlighting the need for better understanding and improvement of patient care.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Gastroenterology & Hepatology
Silvio Danese, Jacinda Tran, Geert D'Haens, David T. Rubin, Nobuo Aoyama, Wen Zhou, Dapo Ilo, Xuan Yao, Yuri Sanchez Gonzalez, Remo Panaccione
Summary: This post hoc analysis evaluated the effects of upadacitinib on fatigue, bowel urgency, and abdominal pain in patients with ulcerative colitis. The results showed that upadacitinib induction treatment significantly reduced abdominal pain and bowel urgency, and also improved fatigue symptoms.
INFLAMMATORY BOWEL DISEASES
(2023)
Review
Gastroenterology & Hepatology
Harris A. Ahmad, James E. East, Remo Panaccione, Simon Travis, James B. Canavan, Keith Usiskin, Michael F. Byrne
Summary: Inflammatory bowel disease, including Crohn's disease and ulcerative colitis, is a condition characterized by uncontrolled inflammation in the gastrointestinal tract. Artificial intelligence is increasingly being used to provide accurate evaluations of endoscopic appearance and histologic activity in patients with inflammatory bowel disease. These AI tools also have the potential to predict treatment response to biologic therapies and improve the standard of care, by personalizing treatment options and reducing costs.
INTESTINAL RESEARCH
(2023)
Review
Gastroenterology & Hepatology
Sudheer Kumar Vuyyuru, Virginia Solitano, Malcolm Hogan, John K. MacDonald, Alexa Zayadi, Claire E. Parker, Bruce E. Sands, Remo Panaccione, Neeraj Narula, Brian G. Feagan, Siddharth Singh, Vipul Jairath, Christopher Ma
Summary: This systematic review and meta-analysis evaluated the efficacy and safety of selective IL-23p19 and IL-12/23p40 inhibitors in patients with moderate-to-severe CD. The results demonstrated that targeting IL-23 is effective and safe for inducing and maintaining clinical and endoscopic remission.
DIGESTIVE DISEASES AND SCIENCES
(2023)
Article
Gastroenterology & Hepatology
Simon Travis, Alison Potts Bleakman, Marla C. Dubinsky, Stefan Schreiber, Remo Panaccione, Toshifumi Hibi, Theresa Hunter Gibble, Cem Kayhan, Christian Atkinson, Christophe Sapin, Eoin J. Flynn, David T. Rubin
Summary: Bowel urgency has a significant impact on the lives of patients from the United States and Europe, and there are disparities between patient and healthcare professional perceptions on the experience and impact of ulcerative colitis symptoms. The CONFIDE study aimed to evaluate these symptoms and communication gaps between patients and healthcare professionals in the US and Europe.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Gastroenterology & Hepatology
Sangmin Lee, Cynthia H. Seow, Kara Nerenberg, Stefania Bertazzon, Yvette Leung, Vivian Huang, Tara Whitten, Stephanie Coward, Remo Panaccione, Gilaad G. Kaplan, Amy Metcalfe
Summary: Attendance at a dedicated IBD-pregnancy clinic improves disease-specific pregnancy knowledge and does not affect perinatal outcomes in pregnant women with IBD.
INFLAMMATORY BOWEL DISEASES
(2023)
Meeting Abstract
Gastroenterology & Hepatology
R. Atreya, P. Irving, M. Fujiya, J. F. Colombel, S. Danese, L. Peyrin-Biroulet, T. Bessissow, R. Panaccione, G. D'Haens, S. van Haaren, E. Neimark, J. Zambrano, Y. Zhang, K. Kligys, M. Ferrante
JOURNAL OF CROHNS & COLITIS
(2023)
Meeting Abstract
Gastroenterology & Hepatology
R. Panaccione, I. Dotan, M. Ferrante, S. Danese, P. Bossuyt, K. Kligys, E. Neimark, J. Zambrano, X. Liao, G. D'Haens
JOURNAL OF CROHNS & COLITIS
(2023)
Meeting Abstract
Gastroenterology & Hepatology
J. Panes, R. Panaccione, B. Sands, C. Gasink, C. Marano, T. Ma, T. Hoops
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Gastroenterology & Hepatology
Remo Panaccione, Silvio Danese, Wen Zhou, Justin Klaff, Dapo Ilo, Xuan Yao, Gweneth Levy, Peter D. R. Higgins, Edward V. Loftus Jr, Su Chen, Yuri Sanchez Gonzalez, Carolyn Leonard, Xavier Hebuterne, James O. Lindsay, Qian Cao, Hiroshi Nakase, Jean-Frederic Colombel, Severine Vermeire
Summary: Upadacitinib demonstrates efficacy and safety for 16-week induction and 52-week maintenance therapy in patients with moderately to severely active ulcerative colitis. Patients without clinical response after 8 weeks' upadacitinib 45 mg induction therapy may benefit from an additional 8 weeks of therapy.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Correction
Gastroenterology & Hepatology
William J. Sandborn, Geert R. D'Haens, Bruce E. Sands, Remo Panaccione, Siew C. Ng, Nervin Lawendy, Nicole Kulisek, Irene Modesto, Xiang Guo, Rajiv Mundayat, Chinyu Su, Ivana Vranic, Julian Panes
JOURNAL OF CROHNS & COLITIS
(2023)